Advertisement

European Journal of Clinical Pharmacology

, Volume 74, Issue 12, pp 1671–1672 | Cite as

Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient

  • Pier Giorgio Cojutti
  • Maria Merelli
  • Paola De Stefanis
  • Cleo Fregonese
  • Francesca Lucchese
  • Matteo Bassetti
  • Federico Pea
Letter to the Editor
  • 52 Downloads

A 48-year-old, 92-kg male presented at the Emergency Department after 5 days of fever, cough, and fatigue. Underlying diseases included scleromyxedema, a rare connective tissue disease of unknown etiology [1], monoclonal gammopathy of undetermined significance (MGUS), and methylenetetrahydrofolate reductase (MTHFR) deficiency-related hyperhomocysteinemia. Because of these diseases, he had had repeated hospital accesses in the previous months, both in hematological and in rheumatological wards. At admission, chest CT scan revealed right-sided pulmonary thickening suggestive of pneumonia. The patient’s clinical conditions rapidly worsened [C-reactive protein (CRP) of 142 mg/L (reference range 0–5 mg/L) and pro-calcitonin (PCT) of 7.06 ng/mL (reference range < 0.10 ng/mL)]. He experienced septic shock, with multiple organ failure and seizure, and was transferred to the intensive care unit (ICU). Estimated creatinine clearance [eCrCL] was 10.1 mL/min/1.73 m2, and continuous venovenous...

Notes

Compliance with ethical standards

Conflict of interest

M. B. has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, AstraZeneca, Bayer, Basilea, Gilead, Menarini, MSD, Pfizer, The Medicines Company, Tetraphase and Vifor. F. P. has received speaker honoraria from Accelerate Diagnostics, Angelini, Astra Zeneca, Basilea Pharmaceutica, Forest, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, Thermo Fisher and attended advisory boards for Basilea Pharmaceutics, Gileads, MSD and Pfizer. All other authors have none to declare.

References

  1. 1.
    Hummers LK (2014) Scleromyxedema. Curr Opin Rheumatol 26(6):658–662.  https://doi.org/10.1097/BOR.0000000000000118 CrossRefPubMedGoogle Scholar
  2. 2.
    Torres A, Mouton JW, Pea F (2016) Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations. Clin Pharmacokinet 55(12):1507–1520.  https://doi.org/10.1007/s40262-016-0418-z CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mendez AS, Steppe M, Schapoval EE (2003) Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J Pharm Biomed Anal 33(5):947–954CrossRefGoogle Scholar
  4. 4.
    Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW (2012) Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 34(4):467–476.  https://doi.org/10.1097/FTD.0b013e31825c4ba6 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Schmitt-Hoffmann A, Nyman L, Roos B, Schleimer M, Sauer J, Nashed N, Brown T, Man A, Weidekamm E (2004) Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 48(7):2576–2580.  https://doi.org/10.1128/aac.48.7.2576-2580.2004 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schmitt-Hoffmann A, Roos B, Schleimer M, Sauer J, Man A, Nashed N, Brown T, Perez A, Weidekamm E, Kovacs P (2004) Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 48(7):2570–2575.  https://doi.org/10.1128/aac.48.7.2570-2575.2004 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of Clinical PharmacologySanta Maria della Misericordia University Hospital of Udine, Azienda Sanitaria Universitaria Integrata di UdineUdineItaly
  2. 2.Department of MedicineUniversity of UdineUdineItaly
  3. 3.Infectious Diseases ClinicSanta Maria della Misericordia University Hospital of Udine, Azienda Sanitaria Universitaria Integrata di UdineUdineItaly
  4. 4.Department of Anaesthesia and Intensive CareSanta Maria della Misericordia University Hospital of Udine, Azienda Sanitaria Universitaria Integrata di UdineUdineItaly
  5. 5.Nephrology, Dialysis and Renal TransplantationSanta Maria della Misericordia University Hospital of Udine, Azienda Sanitaria Universitaria Integrata di UdineUdineItaly

Personalised recommendations